Talon Private Wealth LLC Acquires New Position in Abbott Laboratories $ABT

Talon Private Wealth LLC acquired a new stake in Abbott Laboratories (NYSE:ABT) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,998 shares of the healthcare product maker’s stock, valued at approximately $616,000.

A number of other institutional investors have also modified their holdings of the stock. Resources Management Corp CT ADV raised its position in Abbott Laboratories by 23.9% during the 1st quarter. Resources Management Corp CT ADV now owns 65,853 shares of the healthcare product maker’s stock valued at $6,761,000 after purchasing an additional 12,695 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Abbott Laboratories by 3.3% during the first quarter. Royal Bank of Canada now owns 6,463,522 shares of the healthcare product maker’s stock valued at $663,610,000 after buying an additional 209,060 shares during the period. Empowered Funds LLC raised its holdings in shares of Abbott Laboratories by 73.5% in the first quarter. Empowered Funds LLC now owns 257,761 shares of the healthcare product maker’s stock valued at $26,464,000 after acquiring an additional 109,204 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Abbott Laboratories by 67.4% in the first quarter. The Manufacturers Life Insurance Company now owns 5,116,192 shares of the healthcare product maker’s stock valued at $525,279,000 after acquiring an additional 2,059,108 shares in the last quarter. Finally, Maverick Capital Ltd. purchased a new stake in Abbott Laboratories in the first quarter worth about $180,510,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: UBS reaffirmed a Buy rating on Abbott, supporting the view that the recent pullback has created an attractive entry point. UBS Issues a Buy Rating on Abbott Laboratories
• Positive Sentiment: TD Cowen maintained its Buy rating and set a $115 price target, citing a strengthening nutrition franchise and 2026 growth opportunities. Abbott Laboratories Buy Rating Backed by Growth Drivers
• Positive Sentiment: Recent quarterly results exceeded expectations, with earnings and revenue above consensus and year-over-year revenue growth of 13%. Coverage also highlights record results and raised outlooks during the current earnings season. Companies Reported Record Results and Raised Guidance
• Positive Sentiment: Analysts continue to see long-term expansion in diabetes care, oncology diagnostics and heart-care devices, while Erste Group slightly raised its 2027 EPS forecast to $6.06 from $6.05. Abbott Growth Trends
• Neutral Sentiment: Abbott began a roughly 1,000-patient real-world study of its TriClip heart-valve repair system. The study could strengthen adoption, but it also underscores rising competition from Edwards Lifesciences. Abbott Starts TriClip Study
• Neutral Sentiment: A personal-finance article included Abbott among dividend stocks suitable for long-term passive income, but it offered limited new company-specific information. Dividend Stocks for Passive Income
• Negative Sentiment: UBS lowered its price target from $135 to $125 while retaining a Buy rating, signaling somewhat less near-term upside despite continued confidence in Abbott’s fundamentals.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $108.15 on Thursday. The company has a 50 day moving average price of $92.72 and a 200 day moving average price of $100.73. The firm has a market capitalization of $188.38 billion, a P/E ratio of 35.00, a PEG ratio of 2.08 and a beta of 0.61. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Analyst Upgrades and Downgrades

ABT has been the topic of a number of research reports. Oppenheimer cut their target price on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. The Goldman Sachs Group dropped their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Stifel Nicolaus cut their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a report on Wednesday, April 22nd. Finally, Wells Fargo & Company lifted their price target on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $118.17.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.